

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3	"6407128".pn. "6030988".pn. "6099859".pn.	US-PGPUB; USPAT; EPO	OR	ON	2005/11/05 12:12
L2	4	"6407128".pn. "3062827".pn. "4036957".pn.	US-PGPUB; USPAT; EPO	OR	ON	2005/11/05 12:12
S1	0	metaxalone.ti,ab. same (micronized pulverized micronize micronised)	US-PGPUB; USPAT; EPO	OR	ON	2005/11/05 12:10
S2	1	metaxalone.ti,ab. and (micronized pulverized micronize micronised)	US-PGPUB; USPAT; EPO	OR	ON	2005/11/04 16:02
S3	0	("2005/0163839").URPN.	USPAT	OR	ON	2005/11/04 16:00
S4	9	metaxalone.ti,ab.	US-PGPUB; USPAT; EPO	OR	ON	2005/11/04 16:01
S5	1	metaxalone.ti,ab. and (micronized pulverized micronize micronised microni\$)	US-PGPUB; USPAT; EPO	OR	ON	2005/11/04 16:02
S6	1	(skelaxin metaxalone).ti,ab. and (micronized pulverized micronize micronised microni\$)	US-PGPUB; USPAT; EPO	OR	ON	2005/11/04 16:03
S7	23	("20010024659"   "3062827"   "3993767"   "4036957"   "4058621"   "4208405"   "4784852"   "4792449"   "4820690"   "5785976"   "5840688"   "5977175"   "5989583"   "6030988"   "6099859"   "6103269"   "6114379"   "6143325"   "6197757"   "6207178"   "6265438").PN. OR ("6407128").URPN.	US-PGPUB; USPAT; USOCR	OR	ON	2005/11/04 16:06
S8	2	S7 and (microni\$ or micronized)	US-PGPUB; USPAT; USOCR	OR	ON	2005/11/04 16:59
S9	4	S7 and "sodium lauryl sulfate"	US-PGPUB; USPAT; USOCR	OR	ON	2005/11/04 17:29
S10	1	"6407128".pn.	US-PGPUB; USPAT; USOCR	OR	ON	2005/11/04 17:29
S11	2	"6753011".pn. "6352721".pn.	US-PGPUB; USPAT; EPO	OR	ON	2005/11/04 17:36

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamxg1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 5 AUG 30 CA/Caplus -Increased access to 19th century research documents  
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 8 OCT 03 MATHDI removed from STN  
NEWS 9 OCT 04 CA/Caplus-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America  
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download  
of Caplus documents for use in third-party analysis and  
visualization tools  
NEWS 13 OCT 27 Free KWIC format extended in full-text databases  
NEWS 14 OCT 27 DIOGENES content streamlined  
NEWS 15 OCT 27 EPFULL enhanced with additional content

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:31:29 ON 04 NOV 2005

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 17:31:39 ON 04 NOV 2005

FILE LAST UPDATED: 3 NOV 2005 (20051103/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s metaxalone (L) (micronized pulverized micronize micronised)
    19 METAXALONE
   1035 MICRONIZED
    487 PULVERIZED
     3 MICRONIZE
    133 MICRONISED
     0 MICRONIZED PULVERIZED MICRONIZE MICRONISED
      (MICRONIZED (W) PULVERIZED (W) MICRONIZE (W) MICRONISED)
L1      0 METAXALONE (L) (MICRONIZED PULVERIZED MICRONIZE MICRONISED)
```

```
=> s skelaxin (L) (micronized pulverized micronize micronised)
     4 SKELAXIN
   1035 MICRONIZED
    487 PULVERIZED
     3 MICRONIZE
    133 MICRONISED
     0 MICRONIZED PULVERIZED MICRONIZE MICRONISED
      (MICRONIZED (W) PULVERIZED (W) MICRONIZE (W) MICRONISED)
L2      0 SKELAXIN (L) (MICRONIZED PULVERIZED MICRONIZE MICRONISED)
```

```
=> index health
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                ENTRY      SESSION
FULL ESTIMATED COST                             1.14         1.35
```

INDEX 'ABI-INFORM, ADISCTI, ADISINSIGHT, ADISNEWS, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CBNB, CEN, CHEMLIST, CIN, CONFSCI, CSNB, DISSABS, EMBAL, EMBASE, ENERGY, ENVIROENG, ESBIOBASE, FEDRIP, FOMAD, ...' ENTERED AT 17:33:14 ON 04 NOV 2005

54 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

```
=> s (skelaxin or metaxalone) (L) (micronized or pulverized or micronize or micronised)
    1 FILE CAPLUS
    1 FILE IFIPAT
  49 FILES SEARCHED...
    6 FILE USPATFULL
    1 FILE USPAT2
```

4 FILES HAVE ONE OR MORE ANSWERS, 54 FILES SEARCHED IN STNINDEX

```
L3 QUE (SKELAXIN OR METAXALONE) (L) (MICRONIZED OR PULVERIZED OR MICRONIZE OR
```

MICRONISED)

=> file uspatfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.18	2.53

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 17:34:32 ON 04 NOV 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 3 Nov 2005 (20051103/PD)  
FILE LAST UPDATED: 3 Nov 2005 (20051103/ED)  
HIGHEST GRANTED PATENT NUMBER: US6961956  
HIGHEST APPLICATION PUBLICATION NUMBER: US2005246811  
CA INDEXING IS CURRENT THROUGH 3 Nov 2005 (20051103/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 3 Nov 2005 (20051103/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s (skelaxin or metaxalone) (L) (micronized or pulverized or micronize or  
micronised)

10 SKELAXIN  
111 METAXALONE  
8819 MICRONIZED  
39232 PULVERIZED  
253 MICRONIZE  
1776 MICRONISED

L4 6 (SKELAXIN OR METAXALONE) (L) (MICRONIZED OR PULVERIZED OR MICRON  
IZE OR MICRONISED)

=> d bib abs

L4 ANSWER 1 OF 6 USPATFULL on STN  
AN 2005:188930 USPATFULL  
TI Oral controlled release pharmaceutical composition containing metaxalone  
as active agent  
IN Dudhara, Kamlesh Mohanlal, Baroda, INDIA  
Bhalachandra, Nitin, Dharmadhikari, INDIA  
Rupsinh, Yashoraj, Zala, INDIA  
PA SUN PHARMACEUTICAL INDUSTRIES LIMITED, Mumbai, INDIA, 390020 (non-U.S.  
corporation)  
PI US 2005163839 A1 20050728

AI US 2003-502896 A1 20030129 (10)  
WO 2003-IN14 20030129  
DT Utility  
FS APPLICATION  
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903, US  
CLMN Number of Claims: 41  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 572

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an oral controlled release pharmaceutical composition comprising metaxalone, a pharmaceutically acceptable release rate controlling excipient, and pharmaceutically acceptable excipients, wherein the oral controlled release pharmaceutical composition provides peak plasma levels at a time of about 3 hours or more after oral administration of the composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 14

10 SKELAXIN  
111 METAXALONE  
8819 MICRONIZED  
39232 PULVERIZED  
253 MICRONIZE  
1776 MICRONISED  
L5 6 (SKELAXIN OR METAXALONE) (L) (MICRONIZED OR PULVERIZED OR MICRONIZE OR MICRONISED)

=> d 1-6 bib abs

L5 ANSWER 1 OF 6 USPATFULL on STN  
AN 2005:188930 USPATFULL  
TI Oral controlled release pharmaceutical composition containing metaxalone as active agent  
IN Dudhara, Kamlesh Mohanlal, Baroda, INDIA  
Bhalachandra, Nitin, Dharmadhikari, INDIA  
Rupsinh, Yashoraj, Zala, INDIA  
PA SUN PHARMACEUTICAL INDUSTRIES LIMITED, Mumbai, INDIA, 390020 (non-U.S. corporation)  
PI US 2005163839 A1 20050728  
AI US 2003-502896 A1 20030129 (10)  
WO 2003-IN14 20030129  
DT Utility  
FS APPLICATION  
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903, US  
CLMN Number of Claims: 41  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 572

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an oral controlled release pharmaceutical composition comprising metaxalone, a pharmaceutically acceptable release rate controlling excipient, and pharmaceutically acceptable excipients, wherein the oral controlled release pharmaceutical composition provides peak plasma levels at a time of about 3 hours or more after oral administration of the composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 6 USPATFULL on STN  
AN 2005:88040 USPATFULL  
TI Novel process for the preparation of substantially pure  
5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone

IN Gandhi, Biren Jaiprakash, Baroda, INDIA  
Shah, Samir Rameschandra, Baroda, INDIA  
Chitturi, Trinadha Rao, Baroda, INDIA  
Thennati, Rajamannar, Baroda, INDIA  
PI US 2005075505 A1 20050407  
AI US 2004-501588 A1 20040714 (10)  
WO 2003-IN9 20030113  
PRAI IN 2002-272002 20020114  
DT Utility  
FS APPLICATION  
LREP Mark Pohl, Pharmaceutical Patent Attorneys, 4th Floor, 55 Madison  
Avenue, Morristown, NJ, 07960-7397  
CLMN Number of Claims: 43  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 540  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, a compound of formula (1), is prepared by a novel route, which comprises reacting 3-(3,5-dimethylphenoxy)-2-hydroxypropylamine, a compound of formula (2), or its acid addition salt with a compound of formula (3) (YCOZ) wherein Y and Z are selected from X, CC13CO, 1-imidazolyl or substituted imidazolyl, and OR; wherein X is a halide, preferably chloride, and R is selected from substituted or unsubstituted linear, branched or cyclic alkyl and aryl or heteroaryl radicals. The compound of formula (2) is prepared by treating 2-[(3,5-Dimethylphenoxy)methyl]oxirane with ammonia to yield compound of formula (2), and optionally purifying compound of formula (2) by converting to its acid addition salt.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 6 USPATFULL on STN  
AN 2003:335358 USPATFULL  
TI Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs  
IN Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES  
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES  
Fikstad, David T., Salt Lake City, UT, UNITED STATES  
Zhang, Huiping, Salt Lake City, UT, UNITED STATES  
Gilyar, Chandrashekar, Salt Lake City, UT, UNITED STATES  
PI US 2003236236 A1 20031225  
AI US 2003-444935 A1 20030522 (10)  
RLI Continuation-in-part of Ser. No. US 2000-716029, filed on 17 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2000-751968, filed on 29 Dec 2000, GRANTED, Pat. No. US 6458383 Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, GRANTED, Pat. No. US 6309663  
DT Utility  
FS APPLICATION  
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1614  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs, particularly steroids, are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, preferably a vitamin E substance; and a surfactant. The synergistic effect between the hydrophobic drug and the vitamin E substance results in a pharmaceutical formulation with improved dispersion of both the active

agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 6 USPATFULL on STN  
AN 2003:264858 USPATFULL  
TI Methods and drug delivery systems for the treatment of orofacial diseases  
IN Kochinke, Frank, San Jose, CA, UNITED STATES  
PI US 2003185872 A1 20031002  
AI US 2002-113730 A1 20020327 (10)  
DT Utility  
FS APPLICATION  
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025  
CLMN Number of Claims: 136  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2698

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods of treating various orofacial diseases involving inflammation, infection and/or pain, using intratissue controlled release drug delivery systems. More particularly, the invention relates to methods for localized or targeted administration of a sustained release formulation of an agent such as an anti-inflammatory agent to a specified tissue location within the orofacial environment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 6 USPATFULL on STN  
AN 2002:242824 USPATFULL  
TI Combined diffusion / osmotic pumping drug delivery system  
IN Faour, Joaquina, Buenos Aires, ARGENTINA  
PI US 2002132005 A1 20020919  
US 6753011 B2 20040622  
AI US 2002-47915 A1 20020115 (10)  
RLI Continuation-in-part of Ser. No. US 2000-483282, filed on 14 Jan 2000, GRANTED, Pat. No. US 6352721  
PRAI WO 2001-US562 20010108  
DT Utility  
FS APPLICATION  
LREP INNOVAR, LLC, P O BOX 250647, PLANO, TX, 75025  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 1705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Delivery devices capable of delivering one or more active substances by diffusion through plural micropores in the membrane (4) or by osmotic pumping through one or more preformed passageways (5) in the membrane are provided. The device (1) has an about centrally located expandable core (2) completely surrounded by an active substance-containing layer (3), which is completely surrounded by the membrane. The device is capable of delivering insoluble, slightly soluble, sparingly soluble and very soluble active substances to an environment of use. The preferred delivery rate is zero order. The device can deliver an active substance for a period of about 12-24 hours.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 6 USPATFULL on STN  
AN 2002:45370 USPATFULL  
TI Combined diffusion/osmotic pumping drug delivery system

IN Faour, Joaquina, Buenos Aires, ARGENTINA  
PA Osmotica Corp., Tortola, VIRGIN ISLANDS (BRITISH) (non-U.S. corporation)  
PI US 6352721 B1 20020305  
AI US 2000-483282 20000114 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Spear, James M.  
LREP Matos, Rick, Innovar, L.L.C.  
CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1514

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Delivery devices capable of delivering one or more active substances by diffusion through plural micropores in the membrane or by osmotic pumping through one or more preformed passageways in the membrane are provided. The device has an about centrally located expandable core completely surrounded by an active substance-containing layer, which is completely surrounded by the membrane. The device is capable of delivering insoluble, slightly soluble, sparingly soluble and very soluble active substances to an environment of use. The preferred delivery rate is zero order. The device can deliver an active substance for a period of about 12-24 hours.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	14.84	17.37

STN INTERNATIONAL LOGOFF AT 17:35:11 ON 04 NOV 2005